Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Nguyen, Deborah G ^a   Funk, Juergen ^b   Robbins, Justin B ^a   Crogan Grundy, Candace ^a   Presnell, Sharon C ^a   Singer, Thomas ^b   Roth, Adrian B ^b  

^a Organovo Holdings Inc   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALBUMIN; CD31 ANTIGEN; CYTOCHROME P450; DESMIN; LEVOFLOXACIN; SMOOTH MUSCLE ACTIN; TROVAFLOXACIN; ALBUMINOID; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; LIPOPOLYSACCHARIDE; NAPHTHYRIDINE DERIVATIVE; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1; QUINOLONE DERIVATIVE;

ARTICLE; BIOMIMETICS; BIOPRINTING; CELL CULTURE; CELL JUNCTION; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; ENDOTHELIUM CELL; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER; LIVER CELL; PROTEIN EXPRESSION; STELLATE CELL; TOXIC HEPATITIS; ADVERSE DRUG REACTION; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; IMAGE PROCESSING; METABOLISM; THREE DIMENSIONAL IMAGING;

ALBUMINS; BIOPRINTING; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; CYTOCHROME P-450 CYP3A; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FLUOROQUINOLONES; HEPATOCYTES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LEVOFLOXACIN; LIPOPOLYSACCHARIDES; LIVER; NAPHTHYRIDINES; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE-1;

EID: 84978640780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158674     Document Type: Article

References (43)

1. Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. Annals of internal medicine. 1986; 104(6):826-39. PMID: 3518564.
2. Williams DP, Park BK. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug discovery today. 2003; 8(22):1044-50. PMID: 14690635.
3. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug discovery today. 2003; 8(18):832-7. PMID: 12963319.
4. Boelsterli UA, Lim PL. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicology and applied pharmacology. 2007; 220(1):92-107. doi: 10.1016/j.taap.2006.12.013 PMID: 17275868.
5. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chemical research in toxicology. 1999; 12(5):387-95. doi: 10.1021/tx980249i PMID: 10328748.
6. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug safety: an international journal of medical toxicology and drug experience. 2000; 23(6):483-507. PMID: 11144658.
7. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicologic pathology. 2005; 33(1):1-5. doi: 10.1080/01926230590888306 PMID: 15805049.
8. Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy - is there a connection? The Journal of pharmacology and experimental therapeutics. 2003; 307(1):1-8. doi: 10.1124/jpet.102.041624 PMID: 12954806.
9. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory toxicology and pharmacology: RTP. 2000; 32(1):56-67. doi: 10.1006/rtph.2000.1399 PMID: 11029269.
10. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of toxicology. 2013; 87(8):1315-530. doi: 10.1007/s00204-013-1078-5 PMID: 23974980; PubMed Central PMCID: PMC3753504.
11. Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I. In vitro models for liver toxicity testing. Toxicology research. 2013; 2(1):23-39. doi: 10.1039/C2TX20051A PMID: 23495363; PubMed Central PMCID: PMC3593300.
12. Otu HH, Naxerova K, Ho K, Can H, Nesbitt N, Libermann TA, et al. Restoration of liver mass after injury requires proliferative and not embryonic transcriptional patterns. The Journal of biological chemistry. 2007; 282(15):11197-204. doi: 10.1074/jbc.M608441200 PMID: 17227769.
13. Tostoes RM, Leite SB, Serra M, Jensen J, Bjorquist P, Carrondo MJ, et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology. 2012; 55(4):1227-36. doi: 10.1002/hep.24760 PMID: 22031499.
14. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicology and applied pharmacology. 2013; 268(1):1-16. doi: 10.1016/j.taap.2013.01.012 PMID: 23352505.
15. Messner S, Agarkova I, Moritz W, Kelm JM. Multi-cell type human liver microtissues for hepatotoxicity testing. Archives of toxicology. 2013; 87(1):209-13. doi: 10.1007/s00204-012-0968-2 PMID: 23143619; PubMed Central PMCID: PMC3535351.
16. Olson MJ, Mancini MA, Venkatachalam MA, Roy AK. Hepatocyte cytodifferentiation and cell-to-cell communication. In: Mello WCD, editor. Cell Intercommunication1989.
17. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Second ed: Lippincott Williams and Wilkins; 1999. 789 p.
18. Bhatia SN, Yarmush ML, Toner M. Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts. Journal of biomedical materials research. 1997; 34(2):189-99. PMID: 9029299.
19. Cho CH, Park J, Tilles AW, Berthiaume F, Toner M, Yarmush ML. Layered patterning of hepatocytes in co-culture systems using microfabricated stencils. BioTechniques. 2010; 48(1):47-52. doi: 10.2144/000113317 PMID: 20078427; PubMed Central PMCID: PMC3147300.
20. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nature reviews Molecular cell biology. 2007; 8(10):839-45. doi: 10.1038/nrm2236 PMID: 17684528.
21. Jakab K, Norotte C, Damon B, Marga F, Neagu A, Besch-Williford CL, et al. Tissue engineering by self-assembly of cells printed into topologically defined structures. Tissue engineering Part A. 2008; 14(3):413-21. doi: 10.1089/tea.2007.0173 PMID: 18333793.
22. Robbins J, O'Neill CM, Gorgen V, Shepherd BR, Presnell SC. Bioprinted three-dimensional (3D) human liver constructs provide a model for interrogating liver biology. American Society for Cell Biology; New Orleans, LA2013.
23. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2008; 28(5):503-22. doi: 10.1111/j.1365-2036.2008.03752.x PMID: 18532991.
24. Antoine D, Starkey P, Goldring C, Park BK. Are we closer to finding biomarkers for identifying acute drug-induced liver injury. Future Medicine. 2013; 7(3):383-6.
25. Forgacs G, Jakab K, Neagu A, Mironov V, inventors; The Curators of the University of Missouri, MUSC Foundation for Research Development, assignee. Self-assembling cell aggregates and methods of making engineered tissue using the same. United States of America patent US 8,241,905 B2. 2012.
26. Forgacs G, Jakab K, Neagu A, Mironov V, inventors; The Curators of the University of Missouri, Medical University of South Carolina, MUSC Foundation for Research Development, assignee. Self-assembling cell aggregates and methods of making engineered tissue using the same. United States of America patent US 8,852,932 B2. 2014.
27. Murphy K, Dorfman S, Bauwens L, Sohn G, McDonald T, Leigh-Lancaster C, et al., inventors. Devices, systems, and methods for the fabrication of tissue. United States of America patent US 9,149,952 B2. 2015.
28. Shepherd BR, Robbins J, Gorgen V, Presnell SC, inventors; Organovo, Inc., assignee. Engineered Liver Tissues, Arrays Thereof, and Methods of Making the Same. United States of America patent US 9,222,932 B2. 2015 December 29, 2015.
29. Nguyen DG, King SM, Presnell SC. Engineered Renal Tissues, Arrays Thereof, and Methods of Making the Same. United States of America Patent Office; 2016.
30. Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014; 32(8):773-85. doi: 10.1038/nbt.2958 PMID: 25093879.
31. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005; 97(11):1093-107. doi: 10.1161/01.RES.0000191547.64391.e3 PMID: 16306453.
32. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological reviews. 2008; 88(1):125-72. doi: 10.1152/physrev.00013.2007 PMID: 18195085; PubMed Central PMCID: PMC2888531.
33. Olsen AL, Bloomer SA, Chan EP, Gaca MD, Georges PC, Sackey B, et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. American journal of physiology Gastrointestinal and liver physiology. 2011; 301(1):G110-8. doi: 10.1152/ajpgi.00412.2010 PMID: 21527725; PubMed Central PMCID: PMC3129929.
34. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrobial agents and chemotherapy. 2013; 57(12):6366-9. doi: 10.1128/AAC.01124-13 PMID: 24060875; PubMed Central PMCID: PMC3837889.
35. Lazarczyk DA, Goldstein NS, Gordon SC. Trovafloxacin hepatotoxicity. Digestive diseases and sciences. 2001; 46(4):925-6. PMID: 11330435.
36. Watkins PB. Insight into hepatotoxicity: The troglitazone experience. Hepatology. 2005; 41(2):229-30. doi: 10.1002/hep.20598 PMID: 15657920.
37. Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicological sciences: an official journal of the Society of Toxicology. 2010; 118(1):7-18. doi: 10.1093/toxsci/kfq168 PMID: 20538741; PubMed Central PMCID: PMC2955207.
38. Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. The Journal of pharmacology and experimental therapeutics. 2006; 316(3):1080-7. doi: 10.1124/jpet.105.096347 PMID: 16299187.
39. Robbins JB, O'Neill CM, Gorgen V, Shepherd BR, Presnell SC, editors. Bioprinted Human Liver Tissue With iPSC-Derived Hepatocyte-Like Cells. Stem Cell Meeting on the Mesa; 2013; La Jolla, CA, USA.
40. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, et al. Gene Expression Profiles During Hepatic Stellate Cell Activation in Culture and In Vivo. Gastroenterology. 2007; 132:1937-46. PMID: 17484886
41. Nicholson SC, Webb CD, Moellering RC Jr. Antimicrobial-associated acute hepatitis. Pharmacotherapy. 2002; 22(6):794-6; discussion 6-7. PMID: 12066973.
42. Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicological sciences: an official journal of the Society of Toxicology. 2007; 100(1):259-66. doi: 10.1093/toxsci/kfm218 PMID: 17709330.
43. Kegel V, Pfeiffer E, Burkhardt B, Liu JL, Zeilinger K, Nussler AK, et al. Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human In Vitro Liver Model: An Approach to Study DILI. Mediators Inflamm. 2015; 2015:640631. doi: 10.1155/2015/640631 PMID: 26491234; PubMed Central PMCID: PMCPMC4600928.